Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

Constantine S. Tam, Lynne V. Abruzzo, Katherine I. Lin, Jorge Cortes, Alice Lynn, Michael J. Keating, Deborah A. Thomas, Sherry Pierce, Hagop Kantarjian, Srdan Verstovsek

Blood (2009) 113 (18): 4171–4178.

https://doi.org/10.1182/blood-2008-09-178541

Published: 2009

Journal Articles

Relevance of the immunoglobulin V H somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

Katherine I. Lin, Constantine S. Tam, Michael J. Keating, William G. Wierda, Susan O'Brien, Susan Lerner, Kevin R. Coombes, Ellen Schlette, Alessandra Ferrajoli, Lynn L. Barron, Thomas J. Kipps, Laura Rassenti, Stefan Faderl, Hagop Kantarjian, Lynne V. Abruzzo

Blood (2009) 113 (14): 3168–3171.

https://doi.org/10.1182/blood-2008-10-184853

Published: 2009

Journal Articles

Splenectomy in Patients with Chronic Myeloid Leukemia or Myeloproliferative Diseases: Outcomes, Complications and Prognostic Implications.

Constantine S. Tam, MBBS, Raphael E. Pollock, MD, John Manning, MD, Jorge Cortes, MD, Katherine I. Lin, MBBS BND, Deborah A. Thomas, MD, Lingsha Zhou, Hagop Kantarjian, MD, Srdan Verstovsek, MD

Blood (2007) 110 (11): 2553.

https://doi.org/10.1182/blood.V110.11.2553.2553

Published: 2007

Journal Articles

Cytogenetic Findings and Pattern of Clonal Evolution Determine Survival in Patients with Primary or Secondary Myelofibrosis

Constantine S. Tam, MBBS, Lynne V. Abruzzo, MD, Katherine I. Lin, MBBS BND, Jorge Cortes, MD, Alice Lynn, RN MSN, Michael J. Keating, MBBS, Deborah A. Thomas, MD, Hagop Kantarjian, MD, Srdan Verstovsek, MD

Blood (2007) 110 (11): 1543.

https://doi.org/10.1182/blood.V110.11.1543.1543

Published: 2007

Journal Articles

IgVH Mutational Status Does Not Affect Complete Remission Rate but Is Associated with Reduced Remission Duration in CLL Patients Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR)-Based Therapy.

Katherine I. Lin, MBBS, BND, Constantine S. Tam, MBBS, Lynne V. Abruzzo, MD, William Wierda, MD, Lynn Barron, Susan O’Brien, MD, Thomas Kipps, MD, Laura Rassenti, PhD, Susan Lerner, MS, Hagop Kantarjian, MD, Michael J. Keating, MD

Blood (2007) 110 (11): 753.

https://doi.org/10.1182/blood.V110.11.753.753

Published: 2007

NARROW

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

Relevance of the immunoglobulin V H somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

Splenectomy in Patients with Chronic Myeloid Leukemia or Myeloproliferative Diseases: Outcomes, Complications and Prognostic Implications.

Cytogenetic Findings and Pattern of Clonal Evolution Determine Survival in Patients with Primary or Secondary Myelofibrosis

IgVH Mutational Status Does Not Affect Complete Remission Rate but Is Associated with Reduced Remission Duration in CLL Patients Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR)-Based Therapy.

Email alerts

ASH Publications

American Society of Hematology

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

Relevance of the immunoglobulin V H somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

Splenectomy in Patients with Chronic Myeloid Leukemia or Myeloproliferative Diseases: Outcomes, Complications and Prognostic Implications.

Cytogenetic Findings and Pattern of Clonal Evolution Determine Survival in Patients with Primary or Secondary Myelofibrosis

IgVH Mutational Status Does Not Affect Complete Remission Rate but Is Associated with Reduced Remission Duration in CLL Patients Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR)-Based Therapy.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only